NBPF17P: A Potential Drug Target for Diseases (G401967)

Target Name: NBPF17P

NCBI ID: G401967

NBPF17P

Other Name(s): NBPF23P | Neuroblastoma breakpoint family, member 17, pseudogene | NBPF23 | NBPF member 17, pseudogene

NBPF17P: A Potential Drug Target for Diseases

NBPF17P (NBPF23P) is a protein that is expressed in various tissues of the body, including the brain, muscle, and heart. It is a member of the nuclear factor kappa B (NFkB) signaling pathway, which is a well-established regulator of inflammation, cell proliferation, and survival. The NBPF17P protein has been shown to play a role in several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. As a drug target, NBPF17P is a promising target for the development of new therapies for these diseases.

The NBPF17P protein is composed of 23 amino acid residues and has a calculated molecular weight of 19.1 kDa. It is expressed in a variety of tissues, including the brain, muscle, heart, and pancreas. NBPF17P is a nuclear protein and is predominantly localized to the cytoplasm. It is a protein that can interact with other proteins, including NFkB, which is a transcription factor that plays a central role in the regulation of gene expression.

The NBPF17P protein is involved in several cellular processes, including cell signaling, inflammation, and stress response. One of its functions is to regulate the activity of NFkB, which is a transcription factor that plays a central role in the regulation of gene expression. NFkB is activated by various factors, including stress, cytokines, and chemokines. When NFkB is activated, it regulates the expression of many genes that are involved in cellular processes, including inflammation, cell proliferation, and survival.

NBPF17P is involved in several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. For example, NBPF17P has been shown to be involved in the development of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. Studies have shown that NBPF17P is overexpressed in the brains of individuals with these diseases, and that inhibiting NBPF17P activity may be a potential therapeutic approach.

In addition to its role in disease, NBPF17P is also a potential drug target. The NBPF17P protein has been shown to play a role in several cellular processes, including cell signaling, inflammation, and stress response. As a drug target, NBPF17P is a promising target for the development of new therapies for these diseases.

One approach to targeting NBPF17P is to inhibit its activity with small molecules or antibodies. Small molecules that inhibit NBPF17P activity include inhibitors of the NFkB signaling pathway, such as pdm-P1, a small molecule that inhibits the activity of NFkB. Antibodies that target NBPF17P include monoclonal antibodies (MCAs) that are designed to bind to NBPF17P and prevent it from interacting with other proteins, including NFkB.

In conclusion, NBPF17P is a protein that is involved in several cellular processes, including cell signaling, inflammation, and stress response. It is a member of the NFkB signaling pathway and has been shown to play a role in the development of several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. As a drug target, NBPF17P is a promising target for the development of new therapies for these diseases. The inhibition of NBPF17P activity with small molecules or antibodies may be a promising approach to treating these diseases.

Protein Name: NBPF Member 17, Pseudogene

The "NBPF17P Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about NBPF17P comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets